Home › NCT04239703

Trifecta-Kidney cfDNA-MMDx Study

RecruitingObservational study

Trifecta-Kidney cfDNA-MMDx Study: Comparing the DD-cfDNA Test to MMDx Microarray Test, Central HLA Antibody Test, and Histology.

Who can join

All ages · All sexes

Full eligibility criteria

Inclusion Criteria:

* All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.

Exclusion Criteria:

* Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.

About the study

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

What is being tested

MMDx (diagnostic test)
Prospera (diagnostic test)
HLA antibody (diagnostic test)

Sponsor: University of Alberta · Participants: 300 · Started: Dec 1, 2019

Contact the study team

Konrad S Famulski, PhD · Phone: 1 780 492 1725
Robert Polakowski, PhD · Phone: 1 780 492 5091

Official record on ClinicalTrials.gov — NCT04239703

Locations in the U.S.

Florida	Tampa General Hospital, Tampa
Maryland	The Johns Hopkins University, School of Medicine, Baltimore University of Maryland School of Medicine, Baltimore
Michigan	Detroit Medical Center, Harper University Hospital of Wayne State University, Detroit (Not yet recruiting) Henry Ford Hospital, Detroit
Missouri	Barnes-Jewish Hospital, Washington University at St. Louis, St Louis
Ohio	Cleveland Clinic, Cleveland University Hospitals Cleveland Medical Ctr., Cleveland
Utah	Intermountain Transplant Services, Murray
Virginia	Virginia Commonwealth University Medical Center, Richmond
Washington	Division of Nephrology & UW Organ Transplant Center University of Washington, Seattle

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.